Estrella Immunopharma (ESLA) Competitors $0.88 +0.03 (+2.95%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. GALT, KRRO, FTLF, FATE, NKTX, ALTS, CCCC, GNLX, ACTU, and MISTShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Galectin Therapeutics (GALT), Korro Bio (KRRO), FitLife Brands (FTLF), Fate Therapeutics (FATE), Nkarta (NKTX), ALT5 Sigma (ALTS), C4 Therapeutics (CCCC), Genelux (GNLX), Actuate Therapeutics (ACTU), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Galectin Therapeutics Korro Bio FitLife Brands Fate Therapeutics Nkarta ALT5 Sigma C4 Therapeutics Genelux Actuate Therapeutics Milestone Pharmaceuticals Galectin Therapeutics (NASDAQ:GALT) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Is GALT or ESLA more profitable? Galectin Therapeutics' return on equity of 0.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -216.05% Estrella Immunopharma N/A -1,132.38%-273.91% Do insiders and institutionals hold more shares of GALT or ESLA? 11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer GALT or ESLA? Galectin Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 109.79%. Estrella Immunopharma has a consensus target price of $16.00, indicating a potential upside of 1,726.48%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GALT or ESLA? In the previous week, Galectin Therapeutics had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Galectin Therapeutics' score of 0.85 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment Galectin Therapeutics Positive Estrella Immunopharma Very Positive Which has higher valuation & earnings, GALT or ESLA? Galectin Therapeutics is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$47.05M-$0.72-3.97Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.37 Which has more risk and volatility, GALT or ESLA? Galectin Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. SummaryEstrella Immunopharma beats Galectin Therapeutics on 6 of the 11 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.65M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-3.3720.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book7.307.718.185.63Net Income-$7.31M-$55.11M$3.23B$257.73M7 Day Performance-2.23%0.68%-0.25%0.07%1 Month Performance-7.79%8.22%5.40%8.32%1 Year Performance-40.00%-2.64%26.35%13.78% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.1301 of 5 stars$0.88+2.9%$16.00+1,726.5%-44.3%$31.65MN/A-3.37N/APositive NewsGap DownGALTGalectin Therapeutics2.2471 of 5 stars$2.09-2.8%$6.00+187.1%+17.6%$132.28MN/A-2.909Gap UpKRROKorro Bio1.5125 of 5 stars$14.00+11.3%$102.43+631.6%-74.3%$131.46M$2.27M-1.4870FTLFFitLife Brands4.0475 of 5 stars$13.91+1.2%$20.50+47.4%-19.3%$130.62M$64.47M16.5620High Trading VolumeFATEFate Therapeutics3.6202 of 5 stars$1.10+3.7%$3.83+248.8%-71.0%$125.95M$13.63M-0.74550Gap UpNKTXNkarta1.8141 of 5 stars$1.77+4.4%$14.33+712.1%-74.1%$125.24MN/A-1.17140Positive NewsALTSALT5 Sigma0.1337 of 5 stars$7.17-4.9%N/AN/A$125.12M$12.53M0.00170CCCCC4 Therapeutics2.9923 of 5 stars$1.76+15.5%$12.00+583.8%-67.5%$124.62M$35.58M-1.19150GNLXGenelux1.1999 of 5 stars$3.20+10.3%$17.75+454.7%+17.6%$120.75MN/A-3.6410Gap DownACTUActuate Therapeutics2.7248 of 5 stars$6.09+1.3%$20.50+236.6%N/A$119.49MN/A0.0010Positive NewsMISTMilestone Pharmaceuticals2.7335 of 5 stars$2.22+2.3%$7.00+215.3%-6.6%$118.69M$1M-2.8530Analyst Revision Related Companies and Tools Related Companies Galectin Therapeutics Competitors Korro Bio Competitors FitLife Brands Competitors Fate Therapeutics Competitors Nkarta Competitors ALT5 Sigma Competitors C4 Therapeutics Competitors Genelux Competitors Actuate Therapeutics Competitors Milestone Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLA Stock Alerts